Infosys CEO among highest paid in Indian IT as compensation rose 22% to $9.4 mln last fiscal
Parekh, the longest-serving non-founder CEO at the IT company, earned a fixed salary of 79.4 million rupees and bonuses of 231.8 million rupees.
The largest portion, 495 million rupees, resulted from the chief executive of India's No. 2 IT services firm exercising his stock options.
In comparison, Parekh earned $7.9 million in 2024 and $6.76 million in 2023, with the rise in pay, mainly due to a greater number of stock options exercised during the year.
For the financial year 2025, Infosys reported a revenue growth of 4.2% in constant currency terms, falling short of its forecast of 4.5%-5%. For the current fiscal year, it forecast a flat to 3% growth in revenue, signalling a weaker business environment.
India's $283-billion IT sector is facing another year of slowing growth, partly due to the U.S. tariff policies, which complicate forecasting market conditions in key markets and client segments.
"Majority of Infosys revenue is from the U.S. and other global markets. The compensation is in line and consistent with what companies of this scale and size pay globally. Boards of Indian tech companies are indeed aware and need their leaders to be retained and paid appropriately in this challenging environment," said K Sudarshan, managing director at executive search firm EMA Partners.
K Krithivasan, CEO of Infosys' larger rival Tata Consultancy Services earned $3.11 million, and smaller rival Wipro's CEO Srinivas Pallia earned $6.28 million, according to their latest annual report.
Infosys is one of the two among India's top five IT companies that have retained their CEO at the helm over the last 18-24 months, with HCLTech being the other.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
21 minutes ago
- The Hindu
Rupee falls 2 paise to 86.40 against U.S. dollar in early trade
The rupee depreciated 2 paise to 86.40 against the U.S. dollar in early trade on Wednesday (July 23, 2025), amid outflow of foreign funds and higher crude oil prices. According to forex traders, positive sentiment in domestic equity markets capped a sharp fall in the rupee even as the American currency strengthened after the U.S. announced a trade deal with Japan. At the interbank foreign exchange, the domestic unit opened weak at 86.46 and recovered slightly to trade at 86.40 against the greenback in initial deals, 2 paise lower from its previous closing level. At the end of Tuesday's trading session, the local unit settled at 86.38, down 7 paise over its previous close. This was the rupee's fifth straight session of decline since July 16 when the unit had lost 16 paise and ended at 85.92 against the dollar. Meanwhile, the dollar index, which gauges the greenback's strength against a basket of six currencies, rose 0.04 per cent to 97.15, after the US announced a trade deal with Japan. Brent crude, the global oil benchmark, went up by 0.29% to $68.79 per barrel in futures trade. Analysts said investors are keeping a close watch on the outcome of India-US trade talks ahead of the August 1 deadline as Indian exporters are staring at higher tariffs in American market. If the discussions fail or get delayed, Indian exporters could face fresh pressure -- adding to the rupee's challenges. The US team will visit India in August for the next round of negotiations for the proposed bilateral trade agreement between the two countries. India and the US teams concluded the fifth round of talks for the agreement last week in Washington. Meanwhile, in the domestic equity market, Sensex advanced 209.09 points or 0.25% to 82,395.90, while Nifty rose 60.45 points or 0.24% to 25,121.35. Foreign institutional investors (FIIs) offloaded equities worth ₹3,548.92 crore on a net basis on Tuesday, according to exchange data.
India.com
21 minutes ago
- India.com
Good news for employees of THESE companies as they emerge as India's top..., Ratan Tata's company lead as..., Mukesh Ambani's Reliance at...
Good news for employees of THESE companies as they emerge as India's top..., Ratan Tata's company lead as..., Mukesh Ambani's Reliance at... According to the Randstad Employer Brand Research 2025 (REBR 2025) report released on Tuesday, Tata Group, Google India, and Infosys are among the top 10 most attractive companies to work for in India. Tata Group got top marks for its strong financial position, career growth opportunities, and overall reputation. Google India moved up the list this year to become the second most attractive employer, while Infosys secured the third spot. The State Bank of India (SBI) is the only public sector bank to make it into the top 10. Other companies that made the list include Samsung India, JPMorgan Chase, IBM, Wipro, Reliance Industries, and Dell Technologies. Top 10 most attractive employer brands in India for 2025 Tata Group Google India Infosys Samsung India JPMorganChase IBM Wipro Reliance Industries Dell Technologies Ltd State Bank of India Employees look for work-life balance and more than just a good salary Employees in India highly value their companies' reputation, financial strength, and fair treatment. However, when asked what they look for in an ideal workplace, most people said that work-life balance and good salary with benefits are still lacking and need more attention from employers. Randstad has been studying what job seekers and employees want for the past 25 years globally, and 15 years in India. This year, the report gathered opinions from over 3,500 people in India and more than 1.7 lakh people in 34 countries. The study shows that today's workforce wants more than just a good salary. People are now looking for inclusive, future-ready workplaces that support both their personal and career growth. According to the report, 47 per cent of Indian employees are planning to change jobs in the first half of 2025. This trend is even stronger among Gen Z (51 per cent) and Millennials (50 per cent), who are more eager to explore new opportunities. While 86 per cent of workers in India feel highly motivated, only 5 per cent say they are not engaged at work. Interestingly, even among those who feel disconnected, 67 per cent still plan to switch jobs, showing a strong desire for better work experiences. The study also found that 61 per cent of Indian employees now use AI tools regularly, with Millennials leading the way. Their usage increased by 13 per cent compared to last year. 38 per cent of employees believe that AI is already making a big impact on their work. Reskilling and upskilling have become a top priority, especially for those with higher education. In fact, 9 out of 10 employees say they value employers who offer training and learning opportunities to help them grow.
Mint
21 minutes ago
- Mint
Donald Trump threatens to use import restrictions on foreign drugmakers to reduce prices — Does it affect India?
US President Donald Trump on Tuesday threatened to use import restrictions to force foreign suppliers to reduce drug prices. Speaking at the White House at an event with Republican lawmakers, Trump further warned pharma companies to face a 'lot of problems' if they do not agree to reduce the drug prices in the US. Trump pledged to reduce what consumers must pay for prescription drugs. 'Drug companies will have lot of problems if they don't agree to bring prices down,' he said, making hinting at plans to use trade policy as leverage. 'We are going to get drug prices down… We will use import restrictions to force foreign suppliers to cut drug prices.' The US President's statement comes more than a month after he signed a broad executive order in June directing drugmakers to lower the prices of their prescription drugs to align with what other countries pay. The order said the Trump administration will give drugmakers price targets within a month and, if they fail to make "significant progress", may pursue regulatory actions or measures like importing medicines -- though analysts and legal experts say such steps would be difficult to implement. India plays a key role in supplying pharmaceutical products to the US, including generic drugs and active pharmaceutical ingredients (APIs). According to a report by The Times of India, New Delhi supplies around 35 per cent of all generic drugs prescribed in the US. Therefore, Trump's order to force foreign drugmakers to cut drug prices using import restrictions could significantly affect them, coupled with the fact that India and US have not signed a trade deal as yet. However, in June, Crisil Ratings had said Donald Trump's executive order on reducing prescription drug prices will have a limited impact on Indian pharma companies. Citing the reason behind its observation, the credit rating firm in its report said that despite India exporting over half of its pharmaceutical output, the bulk comprises low-priced generic drugs, which already operate on razor-thin margins, leaving little room for further price cuts to materially affect revenues. "API exports (15 per cent of India's pharma exports) are expected to be broadly unaffected, as it is not a major cost for high-margin originator drugs, abating concerns of pricing pressure," the report said. Generic pharma drugs account for 90 per cent of the prescription sales volume but only 13 per cent of the value spending in the US. Generic drug prices in the US are very low and have lower prices in comparison to economically peer countries, it said.
